An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.
Breast Cancer|HER-2 Positive Breast Cancer|Triple Negative Breast Cancer|ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
DRUG: ganetespib
Objective response rate, Objective response rate is based on RECIST criteria, Week 12
Duration of response and progression free survival, Progressive disease based on RECIST criteria. CT scans at week 6, week 12 and every 6 weeks thereafter for the duration of the study., Every six weeks until progression
The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment in the metastatic setting.